source
- Biotech Scorecard Q3 Highlights Upcoming Trial Readouts from Amylyx and BiogenSTAT’s quarterly biotech scorecard lists fifteen events that could move biotech stocks, focusing on trial readouts and other milestones. Amylyx Pharmaceuticals reported results from its Phase 3 LU…
- Merck ends Phase 2 trial of Alzheimer’s drug MK-1167 from partner NeuphoriaMerck announced it has terminated a mid-stage Phase 2 study of an experimental Alzheimer’s therapy. The drug, called MK-1167, is an oral candidate that was being developed in collaboration with bi…